-
1
-
-
33845360563
-
Epidemiology, treatment and costs of osteoporosis in Germany - The boneEVA study
-
Häussler B, Gothe H, Göl D, et al. Epidemiology, treatment and costs of osteoporosis in Germany - the boneEVA study. Osteoporos Int 2007 18 : 77 84.
-
(2007)
Osteoporos Int
, vol.18
, pp. 77-84
-
-
Häussler, B.1
Gothe, H.2
Göl, D.3
-
3
-
-
34247866550
-
HORIZON pivotal fracture trial: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
-
Black DM, Delmas PD, Eastell R, et al. HORIZON pivotal fracture trial: once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2000 356 : 1809 1822.
-
(2000)
N Engl J Med
, vol.356
, pp. 1809-1822
-
-
Black, D.M.1
Delmas, P.D.2
Eastell, R.3
-
4
-
-
0004851872
-
Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture intervention trial research group
-
Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture intervention trial research group. Lancet 1996 348 : 1535 1541.
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
5
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
-
for the Fracture Interventioin Trial Research Group
-
Cummings SR, Black DM, Thompson DE, et al. for the Fracture Interventioin Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 280 : 2077 2082.
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
6
-
-
4344580653
-
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study
-
Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004 15 : 792 798.
-
(2004)
Osteoporos Int
, vol.15
, pp. 792-798
-
-
Delmas, P.D.1
Recker, R.R.2
Chesnut, C.H.3
-
7
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
-
for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
-
Harris ST, Watts NB, Genant HK, et al. for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999 282 : 1344 1352.
-
(1999)
JAMA
, vol.282
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
8
-
-
0035253489
-
Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women
-
McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001 344 : 333 340.
-
(2001)
N Engl J Med
, vol.344
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
-
9
-
-
12944291524
-
Randomized trial of the effects of risedronate on vertebral fracture in women with established postmenopausal osteoporosis. Vertebral Efficacy in Risedronate Therapy (VERT) Study Group
-
Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fracture in women with established postmenopausal osteoporosis. Vertebral Efficacy in Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000 11 : 83 91.
-
(2000)
Osteoporos Int
, vol.11
, pp. 83-91
-
-
Reginster, J.1
Minne, H.W.2
Sorenson, O.H.3
-
10
-
-
35548986745
-
The cost-effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: A structured review of the literature
-
Fleurence RL, Iglesias CP, Johnson JM The cost-effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007 25 : 913 933.
-
(2007)
Pharmacoeconomics
, vol.25
, pp. 913-933
-
-
Fleurence, R.L.1
Iglesias, C.P.2
Johnson, J.M.3
-
11
-
-
0034518984
-
A Bayesian analysis of bisphosphonates effects and cost-effectiveness in post-menopausal osteoporosis
-
Aursnes I, Storvik G, Gasemyr J, Natvig B. A Bayesian analysis of bisphosphonates effects and cost-effectiveness in post-menopausal osteoporosis. Pharmacoepidemiol Drug Saf 2000 9 : 501 509.
-
(2000)
Pharmacoepidemiol Drug Saf
, vol.9
, pp. 501-509
-
-
Aursnes, I.1
Storvik, G.2
Gasemyr, J.3
Natvig, B.4
-
13
-
-
0035000049
-
Cost effectiveness of nasal calcitonin in postmenopausal women: Use of Cochrane Collaboration methods for meta-analysis within economic evaluation
-
Coyle D, Cranney A, Lee KM, et al. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001 19 : 565 575.
-
(2001)
Pharmacoeconomics
, vol.19
, pp. 565-575
-
-
Coyle, D.1
Cranney, A.2
Lee, K.M.3
-
14
-
-
0029583344
-
A comparison of the effectiveness and cost of treatment for vertebral fractures in women
-
Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 1995 34 : 1167 1171.
-
(1995)
Br J Rheumatol
, vol.34
, pp. 1167-1171
-
-
Francis, R.M.1
Anderson, F.H.2
Torgerson, D.J.3
-
15
-
-
0036733574
-
Short-term cost-effectiveness of bisphosphonates therapies for postmenopausal osteoporotic women at high risk of fracture
-
Grima DT, Burge RT, Becker DL, Tosteson ANA. Short-term cost-effectiveness of bisphosphonates therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002 27 : 448 455.
-
(2002)
P&T
, vol.27
, pp. 448-455
-
-
Grima, D.T.1
Burge, R.T.2
Becker, D.L.3
Tosteson, A.N.A.4
-
16
-
-
0036295858
-
Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate [in Spanish
-
Hart WM, Rubio TC, Burrell A. Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate [in Spanish Rev Esp Enferm Metab Oseas 2002 11 : 97 104.
-
(2002)
Rev Esp Enferm Metab Oseas
, vol.11
, pp. 97-104
-
-
Hart, W.M.1
Rubio, T.C.2
Burrell, A.3
-
17
-
-
0036105480
-
The cost utility of bisphosphonate treatment in established osteoporosis
-
Iglesias CP, Torgerson DJ, Bearne A, Bose U. The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 2002 95 : 305 311.
-
(2002)
Q J Med
, vol.95
, pp. 305-311
-
-
Iglesias, C.P.1
Torgerson, D.J.2
Bearne, A.3
Bose, U.4
-
18
-
-
0037253242
-
Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures
-
Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003 21 : 305 314.
-
(2003)
Pharmacoeconomics
, vol.21
, pp. 305-314
-
-
Johnell, O.1
Jönsson, B.2
Jönsson, L.3
Black, D.4
-
19
-
-
8644256610
-
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
-
Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004 15 : 862 871.
-
(2004)
Osteoporos Int
, vol.15
, pp. 862-871
-
-
Kanis, J.A.1
Borgstrom, F.2
Johnell, O.3
Jonsson, B.4
-
20
-
-
85045798171
-
Treatment of established osteoporosis: A systematic review and cost-utility analysis
-
Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002 6 : 1 146.
-
(2002)
Health Technol Assess
, vol.6
, pp. 1-146
-
-
Kanis, J.A.1
Brazier, J.E.2
Stevenson, M.3
-
21
-
-
33644977852
-
Cost-effectiveness strategies to treat osteoporosis in elderly women
-
Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 99 : 123 131.
-
(2006)
South Med J
, vol.99
, pp. 123-131
-
-
Pfister, A.K.1
Welch, C.A.2
Lester, M.D.3
-
22
-
-
0007650891
-
A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture [in Spanish
-
Rodriguez Escolar C, Fidalgo García ML, Rubio Cebrián S. A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture [in Spanish Aten Primaria 1999 24 : 390 396.
-
(1999)
Aten Primaria
, vol.24
, pp. 390-396
-
-
Rodriguez Escolar, C.1
Fidalgo García, M.L.2
Rubio Cebrián, S.3
-
23
-
-
0031762164
-
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis
-
Rosner AJ, Grima DT, Torrance GW, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998 14 : 559 573.
-
(1998)
Pharmacoeconomics
, vol.14
, pp. 559-573
-
-
Rosner, A.J.1
Grima, D.T.2
Torrance, G.W.3
-
24
-
-
29044436585
-
Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy
-
Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int 2005 16 : 1883 1893.
-
(2005)
Osteoporos Int
, vol.16
, pp. 1883-1893
-
-
Schousboe, J.T.1
Ensrud, K.E.2
Nyman, J.A.3
-
25
-
-
33044494094
-
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
-
Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 9 : 1 160.
-
(2005)
Health Technol Assess
, vol.9
, pp. 1-160
-
-
Stevenson, M.1
Lloyd Jones, M.2
De Nigris, E.3
-
26
-
-
33845353443
-
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
-
Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007 18 : 25 34.
-
(2007)
Osteoporos Int
, vol.18
, pp. 25-34
-
-
Silverman, S.L.1
Watts, N.B.2
Delmas, P.D.3
-
27
-
-
34748856744
-
Using real-world data for coverage and payment decisions: The ISPOR real-world task force report
-
Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world task force report. Value Health 2007 10 : 326 335.
-
(2007)
Value Health
, vol.10
, pp. 326-335
-
-
Garrison, L.P.1
Neumann, P.J.2
Erickson, P.3
-
28
-
-
43149088493
-
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: Modeled Canadian analysis
-
Grima DT, Papaioannou A, Thompson MF, et al. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int 2008 19 : 687 697.
-
(2008)
Osteoporos Int
, vol.19
, pp. 687-697
-
-
Grima, D.T.1
Papaioannou, A.2
Thompson, M.F.3
-
29
-
-
14344252272
-
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability
-
Barbieri M, Drummond M, Wilke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005 8 : 10 23.
-
(2005)
Value Health
, vol.8
, pp. 10-23
-
-
Barbieri, M.1
Drummond, M.2
Wilke, R.3
-
31
-
-
0035178263
-
Challenges for model-based economic evaluation of post-menopausal osteoporosis interventions
-
Tosteson ANA, Jönsson B, Grima DT, et al. Challenges for model-based economic evaluation of post-menopausal osteoporosis interventions. Osteoporos Int 2001 12 : 849 857.
-
(2001)
Osteoporos Int
, vol.12
, pp. 849-857
-
-
Tosteson, A.N.A.1
Jönsson, B.2
Grima, D.T.3
-
32
-
-
33845367564
-
Cost-effectiveness of the treatment and prevention of osteoporosis - A review of the literature and a reference model
-
Zethraeus N, Börgstrom F, Störm O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 2007 18 : 9 23.
-
(2007)
Osteoporos Int
, vol.18
, pp. 9-23
-
-
Zethraeus, N.1
Börgstrom, F.2
Störm, O.3
-
33
-
-
3042690325
-
Pharmacoeconomic analysis of osteoporosis treatment with risedronate
-
Brecht JG, Kruse HP, et al. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 2003 22 : 93 105.
-
(2003)
Int J Clin Pharmacol Res
, vol.22
, pp. 93-105
-
-
Brecht, J.G.1
Kruse, H.P.2
-
34
-
-
34247194211
-
Incidence and economic burden of osteoporotic fractures in the United States, 2005-2025
-
Burge RT, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporotic fractures in the United States, 2005-2025. J Bone Miner Res 2007 22 : 465 475.
-
(2007)
J Bone Miner Res
, vol.22
, pp. 465-475
-
-
Burge, R.T.1
Dawson-Hughes, B.2
Solomon, D.H.3
-
35
-
-
0034971070
-
The cost of osteoporotic fractures in the UK: Projections for 2000-2020
-
Burge RT, Worley D, Johansen A, et al. The cost of osteoporotic fractures in the UK: projections for 2000-2020. J Med Econ 2001 4 : 51 62.
-
(2001)
J Med Econ
, vol.4
, pp. 51-62
-
-
Burge, R.T.1
Worley, D.2
Johansen, A.3
-
36
-
-
29044435582
-
Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatment
-
King AB, Saag KG, Burge RT, et al. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int 2005 16 : 1545 1557.
-
(2005)
Osteoporos Int
, vol.16
, pp. 1545-1557
-
-
King, A.B.1
Saag, K.G.2
Burge, R.T.3
-
37
-
-
33744980719
-
The cost-effectiveness of risedronate in the treatment of osteoporosis: An international perspective
-
Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006 17 : 996 1007.
-
(2006)
Osteoporos Int
, vol.17
, pp. 996-1007
-
-
Borgström, F.1
Carlsson, A.2
Sintonen, H.3
-
39
-
-
0032520990
-
Prävalenz der vertebralen Wirbelkörperdeformationen bei Frauen and Männern in Deutschland
-
Felsenberg D, Wieland E, Hammermeister C, et al. Prävalenz der vertebralen Wirbelkörperdeformationen bei Frauen and Männern in Deutschland. Med Klin 1998 93 : 31 4.
-
(1998)
Med Klin
, vol.93
, pp. 31-34
-
-
Felsenberg, D.1
Wieland, E.2
Hammermeister, C.3
-
40
-
-
34347372696
-
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
-
Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007 18 : 1033 1046.
-
(2007)
Osteoporos Int
, vol.18
, pp. 1033-1046
-
-
Kanis, J.A.1
Oden, A.2
Johnell, O.3
-
41
-
-
33644891898
-
Health component of Consumer Price Index Developing better economic models of osteoporosis: Considerations for the calculation of the relative risk of fracture
-
Federal Statistical Office (Statistics Bundesamt). Available from. ) [Accessed January 20, 2009 D.M.*Palermo L.*Grima D.T.
-
Federal Statistical Office (Statistics Bundesamt). 2005. Health component of Consumer Price Index. Available from: http://www.destatis.de/jetspeed/ portal/cms/Sites/destatis/Internet/EN/Content/Statistics/TimeSeries/ EconomicIndicators/BasicData/Content100/vpi102a.psml) [Accessed January 20, 2009 DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health 2006 9 : 54 8.
-
(2005)
Value Health
, vol.9
, pp. 54-58
-
-
-
42
-
-
1242335072
-
The components of excess mortality after hip fracture
-
Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003 32 : 468 473.
-
(2003)
Bone
, vol.32
, pp. 468-473
-
-
Kanis, J.A.1
Oden, A.2
Johnell, O.3
-
44
-
-
34848898144
-
Excess mortality following hip fracture: The role of underlying health states
-
Tosteson ANA, Gottlieb DJ, Radley DC, et al. Excess mortality following hip fracture: the role of underlying health states. Osteoporos Int 2007 18 : 1463 1472.
-
(2007)
Osteoporos Int
, vol.18
, pp. 1463-1472
-
-
Tosteson, A.N.A.1
Gottlieb, D.J.2
Radley, D.C.3
-
45
-
-
66749109385
-
Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: A comparison to patients with minimal bisphosphonate exposure
-
Delmas PD, Silverman SL, Watts NB Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: a comparison to patients with minimal bisphosphonate exposure. J Bone Miner Res 2007 22 (Suppl. S328.
-
(2007)
J Bone Miner Res
, vol.22
, Issue.SUPPL
-
-
Delmas, P.D.1
Silverman, S.L.2
Watts, N.B.3
-
46
-
-
0035681528
-
Swedish population health-related quality of life results using the EQ-5D
-
Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001 10 : 621 635.
-
(2001)
Qual Life Res
, vol.10
, pp. 621-635
-
-
Burström, K.1
Johannesson, M.2
Diderichsen, F.3
-
47
-
-
1342310684
-
The risk and burden of vertebral fractures in Sweden
-
Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004 15 : 20 6.
-
(2004)
Osteoporos Int
, vol.15
, pp. 20-26
-
-
Kanis, J.A.1
Johnell, O.2
Oden, A.3
-
48
-
-
85031333656
-
Lauer-Taxe Online, available by subscription Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women
-
LAUER-FISCHER GmbH. Available from. [Accessed January 20, 2009 D.*Nguyen N.D.*Milch V.E.,*et al.
-
LAUER-FISCHER GmbH. Lauer-Taxe Online, available by subscription. Available from: http://www.lauer-fischer.de/LF [Accessed January 20, 2009 D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009 301 : 513 521.
-
(2009)
JAMA
, vol.301
, pp. 513-521
-
-
-
49
-
-
33746196684
-
Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment [article in German
-
Bartl R, Goette S, Hadji P, Hammerschmidt T. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment [article in German Dtsch Med Wochenschr 2006 131 : 1257 1262.
-
(2006)
Dtsch Med Wochenschr
, vol.131
, pp. 1257-1262
-
-
Bartl, R.1
Goette, S.2
Hadji, P.3
Hammerschmidt, T.4
-
50
-
-
0035078975
-
Hip fracture incidence in east and West Germany: Reassessment 10 years after unification
-
Wildner M, Clarke DE. Hip fracture incidence in east and West Germany: reassessment 10 years after unification. Osteoporos Int 2001 12 : 136 139.
-
(2001)
Osteoporos Int
, vol.12
, pp. 136-139
-
-
Wildner, M.1
Clarke, D.E.2
-
51
-
-
51149098773
-
The NICE cost-effectiveness threshold: What it is and what that means
-
US Census Bureau. Available from. [Accessed February 2, 2009 C.*Claxton K.*Culyer A.J.
-
US Census Bureau. Selected age groups for the population by race and Hispanic origin in the United States. Available from: http://www.census.gov/ Press-Release/www/releases/archives/race/001839.html [Accessed February 2, 2009 C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008 26 : 733 744.
-
(2008)
Pharmacoeconomics
, vol.26
, pp. 733-744
-
-
-
52
-
-
8844239956
-
Health-economic comparison of three recommended drugs for the treatment of osteoporosis
-
Brecht JG, Kruse HP, Möhrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004 24 : 1 10.
-
(2004)
Int J Clin Pharmacol Res
, vol.24
, pp. 1-10
-
-
Brecht, J.G.1
Kruse, H.P.2
Möhrke, W.3
|